Investigating how a cellular process affects lung scarring
Official title: Macropinocytosis and Pulmonary Fibrosis
Funded at Baylor College of Medicine · NIH-11027660 · Data updated 2026-11-12
This study is looking at how a process that helps cells take in nutrients might play a role in the lung disease pulmonary fibrosis, with the hope of finding new ways to prevent or treat this condition for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $596,179 |
| NIH project number | 1R01HL176934-01 |
| Project ID | NIH-11027660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or those at risk of developing this condition.
✕Less likely to help
Patients with other forms of lung disease unrelated to pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on understanding the role of macropinocytosis, a cellular process that helps cells absorb nutrients, in the development of pulmonary fibrosis, a serious lung disease. The researchers will explore how this process contributes to the formation of scar tissue in the lungs and identify the underlying molecular mechanisms involved. By studying this in laboratory models, they aim to uncover potential therapeutic targets that could help prevent or treat this condition. Patients may benefit from insights gained that could lead to new treatment options for pulmonary fibrosis.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively treat or prevent pulmonary fibrosis.
How similar studies have gone: Previous research has shown promising results in understanding cellular processes related to fibrosis, suggesting potential for success in this area.
Where this research is happening
-
Baylor College of Medicine
Houston, United States Active
Researchers
- Principal investigator: Tsoyi, Konstantin — Baylor College of Medicine
- Study coordinator: Tsoyi, Konstantin
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.